Antiinflammatory potential of nano‐curcumin as an alternative therapeutic agent for the treatment of mild‐to‐moderate hospitalized COVID‐19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi… - Phytotherapy …, 2022 - Wiley Online Library
The present study conducted a placebo‐controlled clinical trial to evaluate the impact of
nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 …
nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 …
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi… - Phytotherapy …, 2022 - eprints.medilam.ac.ir
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi… - Phytotherapy …, 2022 - europepmc.org
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi, AA Ghadiri… - 2022 - pubmed.ncbi.nlm.nih.gov
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi, AA Ghadiri… - 2022 - cabidigitallibrary.org
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo …
A Asadirad, R Nashibi, A Khodadadi… - Phytotherapy …, 2022 - eprints.medilam.ac.ir
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID-19 …